I am an epidemiologist with a long-running interest in the use of real-world data as a means of informing policy and health improvement. I currently oversea a small team of analysts, collaborating with industry, academic institutions and charities to better understand patient treatment pathways, inequalities in care, and the effectiveness of novel therapies.
Projects:
Endometrial Cancer Audit Pilot (ECAP)
Ovarian cancer audit feasibility pilot
Kidney Cancer Quality Performance Indicators
Cholangiocarcinoma (AMMF)
CORECT-R
Real-world Standing Cohorts
Craig Knott
Principal Health Data Analyst
Craig is an epidemiologist by training and has spent more than a decade analysing a range of retrospective population-based datasets.
He started his career at University College London, where he studied the relationship between different dynamics of alcohol consumption and the risk of non-communicable disease, before moving on to the University of Cambridge where he developed natural experimental studies designed to explore the impact of public policy on human behaviour.
Most recently he has moved into pharmacoepidemiology, working with HDI to establish a series of real-world standing cohorts alongside international partners. Here, cancer registration data are linked to myriad healthcare datasets to explore real-world clinical practice, analyse patient survival, and monitor changes in the therapeutic landscape.
Education and Awards:
University College London, 2013-16
– PhD Epidemiology and Public Health
University College London, 2010-13
– MSc Social Epidemiology
Open University, 2004-09
– BSc Social Sciences with Social Policy
Publications:
Variability in Kidney Cancer Treatment and Survival in England
K Fife, C Pearson, C S Knott, A Greaves, G D Stewart, Members of the Kidney Cancer Accord. Variability in Kidney ...
Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study
Seyed Hamidreza Mahmoudpour, Craig Knott, Mairead Kearney, Leo Russo, Patrice Verpillat,Factors associated with ...
Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study
Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year ...
Cohort study to assess geographical variation in cholangiocarcinoma treatment in England
Jose S, Zalin-Miller A, Knott C, Paley L, Tataru D, Morement H, Toledano MB, Khan SA. Cohort study to assess ...
First-line treatment (tx) patterns and overall survival (OS) of patients (pts) with advanced Merkel cell carcinoma (aMCC) in England from 2013-2022: Results of a nationwide observational cohort study
First-line treatment (tx) patterns and overall survival (OS) of patients (pts) with advanced Merkel cell carcinoma ...
First-line treatment patterns and overall survival of patients with advanced Merkel cell carcinoma in England from 2013-2022: results of a nationwide observational cohort study
Knott CS, Mahmoudpour SH, Kearney M, Boutmy E, Verpillat P. First-line treatment patterns and overall survival of ...
Treatments into Routine Clinical Practice for the Treatment of Patients with Advanced or Metastatic Cancers
Mahmoudpour SH, Knott CS, Amin A, Boutmy E, Verpillat P. Integration of Immuno-oncology (IO) Treatments into ...
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer
Goulden S, Heffernan K, Sen Nikitas F, et al. Outcomes of dostarlimab versus chemotherapy in post-platinum ...
Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017
Zalin-Miller A, Jose S, Knott C, Paley L, Tataru D, Morement H, Toledano MB, Khan SA. Regional variation in routes ...
Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer
Hend Hassan; Tameera Rahman; Andrew Bacon; Craig Knott; Isaac Allen; Catherine Huntley; Lucy Loong; Yvonne ...
Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe
Girard N, Wolf J, Kim TM, Leighl N, Knott CS, Li T, Cabrieto J, Diels J, Sermon J, Mahadevia P, Schioppa CA, ...
Trends in incidence, treatment and survival of Merkel cell carcinoma epidemiology in England 2004-2018
Mistry K, Levell NJ, Hollestein, Wakkee M, Hijsten T, Knott CS, et al. Trends in incidence, treatment and survival ...
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Chouaid, C., Bosquet, L., Girard, N. et al. An Adjusted Treatment Comparison Comparing Amivantamab Versus ...
Second primary cancer risks for female and male breast cancer survivors
Isaac Allen; Tameera Rahman; Andrew Bacon; Craig Knott; Sophie Jose; Sally Vernon; Hend Hassan; Catherine ...
Amivantimab versus real-world clinical practice in Europe and the US for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
Girard N, Wolf J, Kron A, Scheffler M, Knott CS Bosquet L et al. Amivantimab versus real-world clinical practice ...
Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England
Kearney M, Knott CS, Mahmoudpour H, Verpillat P. Factors associated with the receipt of systemic treatment (tx) ...
Evolution of the treatment landscape in patients with advanced or metastatic cancers following the approval of immuno-oncology treatments
Mahmoudpour H, Knott CS, Amin A, Boutmy E, Verpillat P. Evolution of the treatment landscape in patients with ...
Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis
Heffernan K, Sen Nikitas FS, Shukla U, Camejo HS, Knott CS. Previously treated recurrent or advanced endometrial ...
Kidney Cancer UK Quality Performance Audit of Kidney Cancer Services in England
Kidney Cancer UK Accord. Kidney Cancer UK Quality Performance Audit of Kidney Cancer Services in England. ...
Comparison of survival outcomes between dostarlimab and comparator treatments (tx) in patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC) in England
Goulden S, Heffernan K, Nikitas FS, Shukla U, Knott CS, Hunger M, Pahwa A, Schade R. Comparison of survival ...
Short-term mortality in ovarian, fallopian tube ad primary peritoneal carcinomas across England
Ovarian Cancer Audit Feasibility Pilot Steering Group. Short-term mortality in ovarian, fallopian tube ad primary ...
Demographics and survival outcomes in patients with advanced or recurrent endometrial cancer (EC) following platinum-based doublet (PBD) in the English real-world (RW) setting
Knott CS, Heffernan K, Nikitas FS, Shukla U, Starkie-Camejo H. 812P Demographics and survival outcomes in patients ...
A registry study of relapsed or refractory multiple myeloma pre-exposed to 3 or more therapies including a proteasome inhibitor, an immunomodulatory agent and cd38-targeted monoclonal antibody therapy in England
Elsada A, Zalin-Miller A, Knott CS, Caravotas L. A registry study of relapsed or refractory multiple myeloma ...
Significant variation in treatment and survival outcomes in stage 2–4 ovarian cancer in England
Sundar SS, Knott CS, Paley L, et al. Significant variation in treatment and survival outcomes in stage 2–4 ovarian ...
Utilising Public Health England Datasets to Establish a Standing Cohort of Patients with Metastatic Bladder Cancer
Davies FJ. Knott CS, Kerr C, Adedokun L, Lockhat DM. Utilising Public Health England Datasets to Establish a ...
Geographic variation in ovarian, fallopian tube and primary peritoneal cancer treatment in England
Ovarian Cancer Audit Feasibility Pilot Steering Group. Geographic variation in ovarian, fallopian tube and primary ...
Further information:
Linkedin profile